Increased apoprotein B in very low density lipoproteins of patients with peripheral vascular disease.
- 1 January 1982
- journal article
- research article
- Published by Wolters Kluwer Health in Arteriosclerosis: An Official Journal of the American Heart Association, Inc.
- Vol. 2 (1), 74-80
- https://doi.org/10.1161/01.atv.2.1.74
Abstract
Lipoprotein compositional studies were carried out in 20 patients with atherosclerotic peripheral vascular disease. Twelve of these patients were normolipidemic, the other eight, hypertriglyceridemic. Ten normolipidemic and 10 hypertriglyceridemic age-matched subjects were used as controls. High density lipoprotein cholesterol levels were markedly reduced in the hypertriglyceridemic subjects, both with (35.1 +/- 5.0 mg/dl) and without (36.2 +/- 11.7 mg/dl) peripheral vascular disease, as compared to the normolipidemic patients (47.0 +/- 6.3 mg/dl) and controls (48.1 +/- 10.0 mg/dl). A decreased relative content of apo C-11 in very low density lipoproteins in the hypertriglyceridemic subjects, as compared to the normolipidemics, was detected by isoelectric focusing. Hypertriglyceridemia in patients with peripheral vascular disease shows a typical Type IV lipoprotein and apoprotein profile. Apoprotein B levels in very and low density lipoproteins were determined by electroimmunodiffusion and selective precipitation with tetramethylurea (r = 0.981 between the two methods). All the patients with peripheral vascular disease showed an increased apo B content in very low density lipoproteins vascular disease showed an increased apo B content in very low density lipoproteins (VLDL) as compared to controls (apo B cholesterol in VLDL = 0.341 +/- 0.124 for peripheral vascular disease patients and 0.236 +/- 0.086 for controls, p less than 0.001). A significant correlation between VLDL cholesterol and apo b levels was detected both in peripheral vascular disease patients and in controls; however, two distinct populations could be clearly separated (slopes of the regression lines: peripheral vascular disease patients = 0.350; controls = 0.215, p less than 0.001). The data suggest a possible discriminatory power of VLDL-apo B levels in patients with peripheral vascular disease independent from other lipoprotein and lipid parameters.This publication has 20 references indexed in Scilit:
- Plasma apolipoprotein B and VLDL-, LDL-, and HDL- cholesterol as risk factors in the development of coronary artery disease in male patients examined by angiographyAtherosclerosis, 1981
- A-IMilano apoprotein. Decreased high density lipoprotein cholesterol levels with significant lipoprotein modifications and without clinical atherosclerosis in an Italian family.Journal of Clinical Investigation, 1980
- Apoproteins and lipids as discriminators of severity of coronary heart diseaseAtherosclerosis, 1980
- Relationship between apolipoproteins and chemical components of lipoproteins in survivors of myocardial infarctionAtherosclerosis, 1980
- The distribution of apo C-II and apo C-III in very low density lipoproteins of normal and type iv subjectsAtherosclerosis, 1980
- Association of coronary atherosclerosis with hyperapobetalipoproteinemia [increased protein but normal cholesterol levels in human plasma low density (beta) lipoproteins].Proceedings of the National Academy of Sciences, 1980
- SERUM HIGH-DENSITY LIPOPROTEINS IN PERIPHERAL VASCULAR DISEASEThe Lancet, 1978
- PLASMA-TRIGLYCERIDES IN REGULATION OF H.D.L.-CHOLESTEROL LEVELSThe Lancet, 1978
- High density lipoprotein as a protective factor against coronary heart diseaseThe American Journal of Medicine, 1977
- THE DISTRIBUTION AND CHEMICAL COMPOSITION OF ULTRACENTRIFUGALLY SEPARATED LIPOPROTEINS IN HUMAN SERUMJournal of Clinical Investigation, 1955